AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 (Seite 18)
eröffnet am 21.03.17 23:52:12 von
neuester Beitrag 19.08.22 13:09:24 von
neuester Beitrag 19.08.22 13:09:24 von
Beiträge: 268
ID: 1.249.254
ID: 1.249.254
Aufrufe heute: 0
Gesamt: 60.613
Gesamt: 60.613
Aktive User: 0
ISIN: US05464T1043 · WKN: A2AA7B · Symbol: 19X
68,76
EUR
+2,54 %
+1,70 EUR
Letzter Kurs 29.04.24 Tradegate
Neuigkeiten
15.04.24 · globenewswire  |
10.04.24 · globenewswire |
01.04.24 · globenewswire |
25.03.24 · globenewswire |
25.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 57,10 | +40,50 | |
| 15,700 | +31,93 | |
| 589,55 | +20,00 | |
| 0,6400 | +18,52 | |
| 1,6930 | +17,24 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7400 | -10,46 | |
| 4,0200 | -10,77 | |
| 23,000 | -16,97 | |
| 2,7280 | -29,14 | |
| 0,7000 | -61,96 |
Beitrag zu dieser Diskussion schreiben
FeedbackWill Axsome Therapeutics (AXSM) Continue to Surge Higher?
http://www.nasdaq.com/article/will-axsome-therapeutics-axsm-….."as AXSM has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company.."
Schaun wa mal
Hier sind doch bestimmt schon News durchgesickert.
Axsome Therapeutics Inc Receives a Buy from Aegis Capital
http://www.analystratings.com/2017/06/20/axsome-therapeutics…...In a report released today, Difei Yang from Aegis Capital reiterated a Buy rating on Axsome Therapeutics Inc (NASDAQ: AXSM), with a price target of $20. The company’s shares closed yesterday at $4.60.
Antwort auf Beitrag Nr.: 55.164.266 von Aurum2010 am 19.06.17 14:22:47
Ich denke AXSM wurde bewusst bis gestern an der Kette gelassen
Heute 5.03 +0.43 (9.24%) somit knapp 25% seit der gestrigen News bzw. nache dem Hexensabbat...
Zitat von Aurum2010: Nette News, die Dame hat was auf dem Kasten wie es scheint.
Interessant ist, dass diese News genau nach dem Hexensabbat kommt
Ich denke AXSM wurde bewusst bis gestern an der Kette gelassen
Heute 5.03 +0.43 (9.24%) somit knapp 25% seit der gestrigen News bzw. nache dem Hexensabbat...
Die $5 ist fast da ,gute Ergebnisse wird diese low float Aktie nahe $10 oder gar drüber pushen .
Should You Invest In Axsome Therapeutics? Monday, May 8, 2017
http://www.talkmarkets.com/content/stocks--equities/should-y…
Final Thoughts
Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA.
I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.
-------------------
Recommendation by Aegis (TGT $20):
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
-----
Recommendation by BTIG (TGT $14 ):
Axsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.
-----
Axsome Therapeutics: ~$4 Biotech Stock A Worthy Investment? May 15 ,2017
https://seekingalpha.com/instablog/498952-bret-jensen/498902…
Should You Invest In Axsome Therapeutics? Monday, May 8, 2017
http://www.talkmarkets.com/content/stocks--equities/should-y…
Final Thoughts
Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA.
I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.
-------------------
Recommendation by Aegis (TGT $20):
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
-----
Recommendation by BTIG (TGT $14 ):
Axsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.
-----
Axsome Therapeutics: ~$4 Biotech Stock A Worthy Investment? May 15 ,2017
https://seekingalpha.com/instablog/498952-bret-jensen/498902…
Trading Spotlight
Heute ist ganzen BIOS sieht gut aus CLVS+50%,Exel +11%
Die Nachricht heute scheint gut anzukommen ....Es wird langsam Zeit das die Aktie mal die $5 knackt .
Antwort auf Beitrag Nr.: 55.164.023 von Biohero am 19.06.17 13:52:33hab gar nicht gemerkt das ich zweimal denselben link oben gepostet habe hier ist die press release
https://finance.yahoo.com/news/axsome-therapeutics-appoints-…
https://finance.yahoo.com/news/axsome-therapeutics-appoints-…
Nette News, die Dame hat was auf dem Kasten wie es scheint.
Interessant ist, dass diese News genau nach dem Hexensabbat kommt
Interessant ist, dass diese News genau nach dem Hexensabbat kommt
Antwort auf Beitrag Nr.: 55.133.963 von Biohero am 13.06.17 20:36:04Nicht die Newsdie ich erwartet habe aber diese neue Direktorin ist Klasse
Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors
http://myrtlepotterconsulting.com/myrtle-potter-and-company/…
Ms. Potter was President, Commercial Operations and Chief Operating Officer of Genentech from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, Ms. Potter was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb, Ms. Potter worked at Merck & Co. for fourteen years in roles of increasing responsibility, including Vice President of an $800 million U.S. pharmaceutical business unit. While at Merck, she started the joint venture entity Astra Merck, which through merger, later became AstraZeneca. She began her career with Procter and Gamble Patient Care Products.
About Myrtle Potter ....weitere infos über diese Person
http://myrtlepotterconsulting.com/myrtle-potter-and-company/…
Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors
http://myrtlepotterconsulting.com/myrtle-potter-and-company/…
Ms. Potter was President, Commercial Operations and Chief Operating Officer of Genentech from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, Ms. Potter was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb, Ms. Potter worked at Merck & Co. for fourteen years in roles of increasing responsibility, including Vice President of an $800 million U.S. pharmaceutical business unit. While at Merck, she started the joint venture entity Astra Merck, which through merger, later became AstraZeneca. She began her career with Procter and Gamble Patient Care Products.
About Myrtle Potter ....weitere infos über diese Person
http://myrtlepotterconsulting.com/myrtle-potter-and-company/…
Durchsuchen
AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017
